Our findings indicate that METTL3 may serve as a novel prognostic biomarker and therapeutic target in CTCL, providing insights into m6A-driven oncogenic processes in this challenging malignancy. This evidence concerns the gene METTL3 and primary cutaneous T-cell non-Hodgkin lymphoma.